Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Am-461. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Am-461 SCHEMBL29567409 | 1.00 | CYP3A4 (1.00) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| Am-461 SCHEMBL14715969 | 0.99 | CYP3A4 (0.98) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| Am-461 SCHEMBL14715972 | 0.99 | CYP3A4 (0.98) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| SCHEMBL14733229 | 0.92 | CYP3A4 (0.85) | CYP3A4PTGDR2L3MBTL1NPSR1EPHX2 | |
| SCHEMBL2361747 | 0.92 | CYP3A4 (0.85) | CYP3A4PTGDR2L3MBTL1ALDH1A1NPSR1 | |
| Am-461 SCHEMBL14715970 | 0.91 | CYP3A4 (0.84) | CYP3A4PTGDR2L3MBTL1NPSR1EPHX2 | |
| SCHEMBL349829 | 0.90 | CYP3A4 (0.82) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| SCHEMBL14733252 | 0.90 | CYP3A4 (0.81) | CYP3A4PTGDR2L3MBTL1NPSR1EPHX2 | |
| SCHEMBL350554 | 0.89 | CYP3A4 (0.81) | CYP3A4PTGDR2L3MBTL1GAAALDH1A1 | |
| SCHEMBL350178 | 0.89 | CYP3A4 (0.81) | CYP3A4PTGDR2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688624-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-06-27 | — | — | US | claimed |
| US-8785393-B2 | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-22 | — | — | US | claimed |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-28 | — | — | US | claimed |
| EP-2521713-A2 | DP2 ANTAGONIST AND USES THEREOF | Panmira Pharmaceuticals, LLC (US) | 2012-11-14 | — | — | EP | claimed |
| EP-2480225-A2 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | Panmira Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | claimed |
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| EP-2461809-A2 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | Panmira Pharmaceuticals, LLC (US) | 2012-06-13 | — | — | EP | claimed |
| US-8071807-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-12-06 | — | — | US | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| WO-2011085033-A2 | DP2 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | claimed |
| WO-2011014587-A2 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| WO-2011014588-A2 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-9994905-B2 | Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome | BROWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994905-B2 | Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome | BROWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PTGER2, P2RY2, TBXA2R | PTGDR2 5/4885CYP3A4 4160/4885L3MBTL1 4833/4885 |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1441/4885L3MBTL1 4068/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1441/4885L3MBTL1 4068/4885 |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | BDKRB2, TRPV2, CYSLTR2 | PTGDR2 14/4885CYP3A4 4028/4885L3MBTL1 4127/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 1367/4885L3MBTL1 4395/4885 |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGDR2, PTGES2 | PTGDR2 2/4885CYP3A4 2497/4885L3MBTL1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.